Psychopharmacology and psychotherapy for the treatment of adults with ADHD - A systematic review of available meta-analyses

CNS Spectrums

Volumn 18, Issue 6, 2013, Pages 296-306

  Moriyama, Tais S ^a,b,c   Polanczyk, Guilherme V ^a,c   Terzi, Fernanda S ^c   Faria, Kauy M ^c   Rohde, Luis A ^a,d  

^a National Institute of Developmental Psychiatry for Children and Adolescents (INCT CNPq)   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

ADHD; adults; inattention; stimulants; treatment

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; DESIPRAMINE; DEXAMPHETAMINE; LISDEXAMFETAMINE; LITHIUM; LONG ACTING DRUG; METHYLPHENIDATE; MODAFINIL; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; SHORT ACTING DRUG;

ADULT; ATTENTION DEFICIT DISORDER; COGNITIVE THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84887475360     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285291300031X     Document Type: Review

References (45)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007; 164(6): 942-948.
2. Lopez-Munoz F, Alamo C, Quintero-Gutierrez FJ, Garcia-Garcia P. A bibliometric study of international scientific productivity in attention-deficit hyperactivity disorder covering the period 1980-2005. Eur Child Adolesc Psychiatry. 2008; 17(6): 381-391.
3. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007; 190: 402-409.
4. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006; 36(2): 159-165.
5. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009; 194(3): 204-211.
6. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006; 163(4): 716-723.
7. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord. 2005; 9(2): 384-391.
8. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Cmaj. 2001; 165(11): 1475-1488.
9. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/ hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002; 22(5): 468-473.
10. Faraone SV, Biederman J. Efficacy of Adderall for Attention-Deficit/ Hyperactivity Disorder: a metaanalysis. J Atten Disord. 2002; 6(2): 69-75.
11. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010; 19(4): 353-364.
12. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999; 38(12): 1551-1559.
13. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta- analysis and metaregression analysis. Psychopharmacology (Berl). 2007; 194(2): 197-209.
14. Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord. 2011; 15(8): 674-683.
15. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011; 11: 176.
16. Klassen A, Miller A, Raina P, Lee SK, Olsen L. Attentiondeficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry. 1999; 44(10): 1007-1016.
17. Bjornstad G, Montgomery P. Family therapy for attention-deficit disorder or attention-deficit/ hyperactivity disorder in children and adolescents. Cochrane Database Syst Rev. 2005(2): CD005042.
18. Majewicz-Hefley A, Carlson JS. A meta-analysis of combined treatments for children diagnosed with ADHD. J Atten Disord. 2007; 10(3): 239-250.
19. Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM. Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev. 2008; 28(5): 783-800.
20. Fabiano GA, Pelham Jr WE, Coles EK, et al. A metaanalysis of behavioral treatments for attention-deficit/ hyperactivity disorder. Clin Psychol Rev. 2009; 29(2): 129-140.
21. Zwi M, Jones H, Thorgaard C, York A, Dennis JA. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2011(12): CD003018.
22. Storebo OJ, Skoog M, Damm D, et al. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2011(12): CD008223.
23. Faraone SV. Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/ Hyperactivity Disorder in Youths. P T. 2009; 34(12): 678-694.
24. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed. 2006; 8(4): 4.
25. Seixas M, Weiss M, Muller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012; 26(6): 753-765.
26. Ebert D, Krause J, Roth-Sackenheim C. ADHS im Erwachsenenalter - Leitlinien auf der Basis eines Expertenkonsensus mit Unterstü tzung der DGPPN. Nervenarzt. 2003; 74: 939-946.
27. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007; 21(1): 10-41.
28. National Institute of Health and Clinical Excelence (NICE). Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults. 2008 [cited 2012 12 September]; Available from: http:// www.nice.org.uk/nicemedia/live/12061/42059/42059.pdf.
29. The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA), Canadian ADHD Practice Guidelines, 2011, CADDRA: Toronto.
30. American Academy of Pediatrics (AAP). ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2011; 128(5): 1007-1022.
31. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attentiondeficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7): 894-921.
32. Faraone SV, Spencer T, AleardiM, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol. 2004; 24(1): 24-29.
33. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci. 2011; 65(7): 611-617.
34. Verbeeck W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. Adv Ther. 2009; 26(2): 170-184.
35. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl). 2008; 197(1): 1-11.
36. Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database Syst Rev. 2011(6): CD007813.
37. Meszaros A, Czobor P, Balint S, et al. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol. 2009; 12(8): 1137-1147.
38. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010; 71(6): 754-763.
39. Linderkamp F, Lauth G. The Efficacy of Pharmacological versus Psychotherapeutic Therapies in Adults with Attention Deficit/Hyperactivity Disorder (ADHD): An Empirical Meta-Analysis. Verhaltenstherapie. 2011; 21: 229-238.
40. Michielsen M, Semeijn E, Comijs HC, et al. Prevalence of attention-deficit hyperactivity disorder in older adults in The Netherlands. Br J Psychiatry. 2012.
41. Weiss MD, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006; 67(Suppl 8): 38-45.
42. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 2005; 159(6): 572-578.
43. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008; 42(1): 24-31.
44. Lawson KA, Johnsrud M, Hodgkins P, Sasane R, Crismon ML. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther. 2012; 34(4): 944-956; e4.
45. Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. Jama. 2010; 304(8): 875-880.